Inspections, Compliance, Enforcement, and Criminal Investigations

Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd. - Close Out Letter 4/25/18



Black HHS-Blue FDA Logo



10903 New Hampshire Avenue
Silver Spring, MD 20993 

April 25, 2018

Daniel (NMI) Chemouny
General Manager
Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd.
No. 1889 Jingliu Road, Linjiang Industrial Zone
Hangzhou, Zhejiang, 311228 P.R.C.

Reference: FEI 3009271645

Dear Mr. Chemouny:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter: 320-17-33 dated April 5, 2017. Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.


Rebecca Parrilla
Compliance Officer
Division of Drug Quality I

Page Last Updated: 04/26/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English